藥明康德(02359.HK)建議發行新股 A股最多募65.28億人民幣
藥明康德(02359.HK)公布,建議根據特別授權,向不少於6名特定對象發行不超過6,820.54萬股新H股。募集資金擬用於併購;擴展境外經營;建設常熟研發一體化項目;償還貸款;及補充營運資金。
同時,建議向不超過35名特定對象非公開發行不超過7,500萬股新A股。募集資金最多65.28億人民幣,擬用於一般營運資金及項目投入,主要包括無錫合全藥業新藥製劑開發服務及製劑生產一期、常州合全新藥生產和研發一體化項目及常州合全新藥生產和研發中心等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.